folder

Age-associated clinical patterns in paediatric myocarditis: left ventricular function as the key early risk stratifier

Authors

  • Franziska Seidel
  • Cynthia Huber
  • Bernd Opgen-Rhein
  • Martin Boehne
  • Johannes Weickmann
  • Tobias Hecht
  • Felix Anderheiden
  • Katja Reineker
  • Axel Rentzsch
  • Gesa Wiegand
  • Dorothée Böcker
  • Daniela Kiski
  • Marcus Fischer
  • Wiebke Frede
  • Bettina Ruf
  • Konstantin Papakostas
  • Gleb Tarusinov
  • Inga Voges
  • Michael Kaestner
  • Kerstin Gummel
  • Assunta Schiebel
  • Jennifer Kramp
  • Ulrike Herberg
  • Gunter Kerst
  • Bardo Wannenmacher
  • Eva Gatzweiler
  • Walter Knirsch
  • Nele Rolfs
  • Eicke Schwanzkopf
  • Tania Garfias-Veitl
  • Thomas Pickardt
  • André Rudolph
  • Jens Böhmer
  • Tim Friede
  • Stephan Schubert
  • Daniel Messroghli

Journal

  • ESC Heart Failure

Citation

  • ESC Heart Fail

Abstract

  • BACKGROUND AND AIMS: In myocarditis, early identification of high-risk patients is essential, robust prognostic markers are lacking. We aimed to identify early clinical risk stratifier at index hospitalization for major adverse cardiovascular events (MACE). METHODS: We analysed 725 paediatric patients with possible/definite myocarditis enrolled in the prospective multicentre MYKKE registry (2013-2024). MACE included mechanical circulatory support (MCS), heart transplantation, or death during initial admission. Model-based recursive partitioning (MOB) and bootstrap-based logistic regression with multiple imputation were applied for risk stratifier selection out of 20 baseline variables. The model was externally validated in the Swedish SWEDCON- cohort (n = 243). Discrimination was assessed by the area under the curve (AUC). RESULTS: Among 725 patients (median age 14.3 years [IQR 4.0-16.4]; 33% female), 88 (12.2%) experienced MACE (MCS 10.9%, transplantation 4.3%, death 2.2%). MOB identified left ventricular ejection fraction (LVEF) ≤ 39% as the only stable risk stratifier, delineating a "heart failure type" in younger children (1.9 years; LVEF 24%), and a "chest pain type" in adolescents with preserved LVEF (15.6 years; LVEF 59%). LVEF was confirmed as the sole robust risk stratifier (OR per 1% increase: 0.90 ; 95% CI 0.881-0.917; p < 0.01; AUC 0.90, 95% CI 0.896-0.903). In SWEDCON (7.4% MACE), discrimination was maintained (AUC 0.894, 95% CI 0.80-0.991). CONCLUSION: Reduced LVEF at presentation was the only reproducible and externally validated risk stratifier of MACE during index hospitalization. Two age-associated clinical patterns were observed: a high-risk "heart failure type" in younger children and low-risk "chest pain type" in adolescents.


DOI

doi:10.1093/eschf/xvag259